"Designing Growth Strategies is in our DNA"

Tuberculosis (TB) Diagnostics Market Size, Share & COVID-19 Impact Analysis, By Type (Culture-based Diagnostics, Sputum Smear Microscopy, Rapid Molecular Diagnostics, and Others), By End-user (Diagnostics Laboratories and Hospitals), and Regional Forecast, 2023-2030

Region : Global | Format: PDF | Report ID: FBI102009



Play Audio Listen to Audio Version

Global tuberculosis (TB) diagnostics market size was valued at USD 1.93 billion in 2022 and is projected to reach USD 3.19 billion by 2030, exhibiting a CAGR of 5.6% during 2023-2030. North America dominated the global market with a share of 29.01% in 2022.

Tuberculosis is a contagious disorder caused by a type of bacteria called Mycobacterium tuberculosis. The infection usually attacks the patient’s lungs. The infection can also attack other body parts such as the brain and spine.

Tuberculosis diagnosis can be performed through skin tests and blood tests. The increasing prevalence of this disorder has increased the need for accurate and efficient diagnostic tests to control its spread. This factor is expected to significantly boost the demand for tuberculosis diagnostics in the coming years.

The tuberculosis diagnostics market growth is attributed to increasing TB incidences, growing awareness about the disease, and increased demand for tuberculosis diagnostics to control the disease burden. Furthermore, the rising focus of the market players on the approval and commercialization of their products for TB diagnoses has also been boosting market growth.

  • In August 2021, bioMérieux SA announced the launch of an interferon gamma release assay in association with a desktop immunoassay analyzer, which could be used to detect Mycobacterium tuberculosis in blood samples.


Declining Diagnosis of Tuberculosis Negatively Impacted Market Growth

The COVID-19 pandemic resulted in a decline in demand for tuberculosis diagnostic products during the pandemic. This factor was due to the significant decline in patient volumes for TB diagnosis.

The COVID-19 pandemic caused a decline in the rate of TB testing across the high-burden regions of the global market. Despite the strong infectious nature of the disease, during the initial days of the pandemic, the resources devoted to tuberculosis diagnosis programs were diverted to fight against the coronavirus pandemic.

As the cases attributable to COVID-19 increased worldwide, in 2020, various health workers, testing machines, laboratories, and health centers were diverted from tuberculosis care to COVID-19 care.

  • For instance, according to the Global Fund surveys in March 2021, in the top 13 high TB burden countries, the number of patients undergoing TB testing experienced an estimated decline of 29.0% as compared to the prior year. Moreover, testing for the more severe form of the disease, including antimicrobial resistance, and multidrug-resistant TB experienced a decline of 45.0% compared to the prior year.

The market players also experienced a decline in revenues due to decreased sales of their TB diagnosis instruments and consumables during the pandemic. For instance, bioMérieux SA’s immunoassay business segment, which includes tuberculosis diagnostics, witnessed a decline of -9.7% in 2020 compared to the prior year.

However, there was a significant rebound for the market in 2021, as TB testing increased significantly, especially in high-burden countries. As lockdown restrictions were lifted, the testing levels for tuberculosis increased and are likely to gain similar levels of procedural volume during the forecast period as it was before the pandemic.


Request a Free sample to learn more about this report.

Increased Public-Private Partnerships to Boost Market Growth

In the past few years, there has been an increase in public-private partnerships. The public-private partnerships have a strong positive impact on the market as they contribute to the expansion of tuberculosis diagnosis utilizing international healthcare standards. In the South Asia region, the private health sector provides a significant proportion of diagnostics for diseases, such as tuberculosis, as per government initiatives. Furthermore, government initiatives for increasing awareness regarding the disease and its early diagnosis are also expected to boost the market.

  • For instance, as per the Ministry of Health & Family Welfare, in 2018, the Revised National Tuberculosis Control Programme (RNTCP) had a total of 685 collaborations with civil society/partners from all states of India.

Developments in terms of private-public partnerships are expected to positively impact the TB diagnostics market. In February 2023, Roche Diagnostics announced the enhancement of its partnership with the U.S. Centers for Disease Control and Prevention (CDC). This collaboration aims to bolster laboratory capacities in countries that have been heavily impacted by tuberculosis outbreaks. Such public-private partnerships are driving the growth of the global market.


Favorable Government Policies to Surge the Demand for Tuberculosis (TB) Diagnostics

Governments have increased the policies for the diagnosis of tuberculosis to reduce tuberculosis burden globally. The demand for diagnosis is expected to grow over the next few years, as there is a strong increase in the levels of awareness amongst countries regarding the severity of the disease. Many countries have emphasized the development of policies to increase the diagnosis rates for tuberculosis.

Factors, such as the high incidence of tuberculosis in high-burden countries and increasing demand for TB testing, further increase the need for government policies and regulations to improve tuberculosis diagnosis rates. Furthermore, the rising awareness in high TB burden countries where the key focus is to reduce tuberculosis cases is expected to strongly propel the sales of tuberculosis diagnostics in the coming years.

Tuberculosis incidence has been growing at a faster pace every year worldwide. For instance, as per the India TB Report 2022, the total number of TB patients, including new & relapse cases notified during 2021 was approximately 1.9 million, which was 19.0% higher than in 2020. Due to such high TB incidence rates, governments from different countries have increased their focus on improving their healthcare expenditure for tuberculosis diagnosis and care.

  • According to the India TB Report 2022, India spent approximately USD 399.7 million in 2019-20, experiencing an increase of 39.9% in expenditure compared to 2018-19 for its national TB elimination program.

To reduce the incidence of TB, the government has been releasing policies, leading to strong growth prospects in the global market.

  • For instance, in September 2022, the President of India, launched Pradhan Mantri TB Mukt Bharat Abhiyaan, with a vision to eliminate TB by 2025.

Such policies and government initiatives are expected to fuel the market growth during the forecast period.

Rising Incidence of Tuberculosis in High-Burden Countries to Boost Market Growth

One of the most critical drivers that are positively impacting the market growth is the significant increase in the incidence of this disease across emerging countries. For instance, over the past few decades, there has been a surge in patient population suffering from tuberculosis. This factor led to increased demand for research into effective diagnostic technologies for improved patient outcomes and greater accuracy in the diagnosis of these conditions.

  • According to the Public Health Agency of Canada 2021, Canada reported a total of 1,904 active tuberculosis cases in 2021, with an incidence rate of 5.0 cases per 100,000 people. The incidence rate differed by gender, with 4.5 cases per 100,000 for females and 5.5 cases per 100,000 for males.

  • As per the WHO Global Tuberculosis Report 2022, in 2021, approximately 10.6 million individuals fell ill with tuberculosis globally, representing 4.5% rise from 10.1 million cases reported in 2020. Likewise, between 2020 and 2021, there was an estimated 3.6% increase in tuberculosis incidence rate (new cases per 100,000 populations per year).

Such strong incidence rates and increasing demand for TB diagnoses are expected to propel the market growth in the coming years.


Limitations of Existing Tuberculosis (TB) Diagnostics to Impede Market Growth

Despite a critical and increased need for advanced diagnostics technologies for these diseases, there are a few limitations that may hamper the market growth over the forecast period.

For instance, certain technical complexities associated with tuberculosis diagnostics can act as a major restraining factor for the market during the forecast period. The higher degree of technical challenges in developing these diagnostic technologies is one of the key reasons limiting the overall market growth.

  • As per a research published in the IntechOpen in 2019, sputum smear microscopy was the most commonly used diagnostic test for TB but had limitations such as low sensitivity. False positive results may occur in children, older people, and HIV-infected patients. Furthermore, it also cannot be used to diagnose extrapulmonary TB.

  • The same research stated that GeneXpert MTB/RIF assay may have some technical limitations such as the short shelf life of the cartridges (only 18 months) requirement and a very stable electricity supply requirement.

Such technical limitations associated with tuberculosis diagnostics are expected to hamper the market growth during the forecast timeframe.


By Type Analysis

To know how our report can help streamline your business, Speak to Analyst

New Product Launches to Accelerate the Growth of Rapid Molecular Diagnostics Segment to Dominate

On the basis of type, the market is segmented into culture-based diagnostics, sputum smear microscopy, rapid molecular diagnostics, and others.

The rapid molecular diagnostics segment dominated the market in 2022 and is estimated to hold a significant market share throughout the forecast period. The segment's growth is attributed to the efficiency and accuracy associated with rapid molecular diagnostics for TB diagnosis. New product launches in the rapid molecular diagnostics segment are also anticipated to further drive the segment's growth during the forecast period.

  • For instance, in March 2023, Illumina Inc. and GenoScreen collaboratively introduced a comprehensive solution that combines Illumina products with the GenoScreen Deeplex Myc-TB assay. This package utilizes targeted Next-Generation Sequencing (NGS) technology to enable rapid and thorough detection of drug resistance in tuberculosis cases. Such new product launches are expected to drive segmental growth over the forecast period.

Furthermore, the culture-based diagnostics segment is expected to grow substantially during the forecast period. The segment's growth is attributed to rising TB incidence, which is increasing the demand for efficient, technologically advanced diagnostics.

By End-user Analysis

Strong Presence of Diagnostic Laboratories to Boost the Segment’s Growth 

Based on end-user, the market is bifurcated into diagnostic laboratories and hospitals. The diagnostic laboratories segment accounted for a significant share of the market. The segment's growth is due to the strong presence of diagnostic laboratories worldwide. Moreover, an increasing trend of TB diagnosis being conducted in these diagnostic laboratories is responsible for the segment’s growth. 

  • For instance, as of May 2021, there were approximately 29,227 diagnostic & medical laboratories in the U.S. The presence of numerous institutions may favor the expansion of the segment in the projected years.

The hospitals segment is estimated to grow at a significant CAGR during the forecast period owing to the substantial number of tuberculosis diagnosis procedures conducted in hospitals.

  • For instance, according to Verdict Media Limited, in June 2022, one of the key countries in the global market, India, had an estimated 69,000 public and private hospitals. In emerging countries, including India, hospitals will play an important role as they are expected to conduct a significant number of these diagnostic procedures.


North America Tuberculosis (TB) Diagnostics Market Size, 2022 (USD Billion)

To get more information on the regional analysis of this market, Request a Free sample

The market size in North America stood at USD 0.56 billion in 2022. The robust tuberculosis (TB) diagnostics market share of the region is due to the increasing prevalence of TB, which has been boosting the number of TB diagnosis being conducted in North America. Moreover, the strong presence of market players in this region is expected to contribute to the market growth during the forecast period.

Europe captured a substantial market share in 2022. The segment's growth is attributable to the increasing demand for TB diagnostics such as rapid molecular diagnostics in Europe and initiatives undertaken by the European government agencies to increase the number of diagnostic laboratories in key countries such as the U.K.

Asia Pacific is estimated to witness a significant CAGR in the market during the forecast period. The improvement in healthcare infrastructure in Asian countries, the high burden of TB disease in this region, and the increasing demand among individuals for better treatment outcomes are driving the market growth in Asia Pacific.

  • For instance, according to the TUBERCULOSIS SURVEILLANCE CENTER report in 2022, during 2021, there were a total of 11,519 newly reported cases of tuberculosis in Japan, resulting in a notification rate of 9.2 per 100,000 populations.

Latin America and the Middle East & Africa regions are expected to expand at a comparatively low CAGR during the forecast period. These regions are expected to witness substantial growth during the forecast period, owing to an increasing number of companies penetrating these regions to expand their geographic presence.


Market Players with Strong Focus on Expansion of Tuberculosis (TB) Diagnostics Portfolio to Hold Major Market Share

bioMérieux SA, F. Hoffmann-La Roche Ltd., and Abbott are the prominent players in the market and accounted for significant market share in 2022.

bioMérieux SA dominated the market in 2022. The company’s market dominance is due to its strong product portfolio for test types such as IGRA tests and continuous novel product launches in the market. The company has a considerably strong product portfolio, including VIDAS TB-IGRA.

  • In March 2021, bioMérieux SA announced that it received CE mark approval from the European Union for its TB IGRA test on VIDAS. The test is used for the diagnosis of latent TB infection.

Other significant players, including Cepheid (Danaher), Thermo Fisher, and Qiagen are increasing their emphasis on research & development activities for the development of innovative diagnostics and to strengthen their presence in the global market.



  • May 2022 – F. Hoffmann-La Roche Ltd entered into a partnership with the Global Fund to support low and middle-income countries in strengthening critical diagnosis infrastructure against infectious diseases.

  • March 2022 – Thermo Fisher Scientific Inc. launched the SeqStudio Flex Series Genetic Analyzer for research & development of infectious disease detection, which is expected to expand the company's product portfolio in the market.

  • February 2022 – QIAGEN announced that its QuantiFERON tuberculosis testing solution received the approval of the fourth generation of a modern gold standard test in China.

  • July 2021 – F. Hoffmann-La Roche Ltd. announced that WHO included the company’s products cobas MTB and cobas MTB-RIF/INH tests as Nucleic Acid Amplification Tests (NAATs). These products are nucleic acid testing products used to detect tuberculosis and drug resistant TB.

  • March 2021 – Hologic, Inc. announced the CE marking of its tuberculosis IGRA test on VIDAS. VIDAS TB-IGRA is an automated assay that helps in the diagnosis of infection with Mycobacterium tuberculosis.


An Infographic Representation of Tuberculosis (TB) Diagnostics Market

To get information on various segments, share your queries with us

The research report provides a detailed competitive landscape. It focuses on key points such as new product launches in the market. Additionally, it includes the incidence of tuberculosis and key industry developments such as partnerships, mergers, and acquisitions. Furthermore, the report covers regional analysis of different segments, company profiles of key market players, and the impact of COVID-19 on the market. The report consists of qualitative and quantitative insights contributing to the market growth.

Report Scope & Segmentation



Study Period


Base Year


Estimated Year


Forecast Period


Historical Period


Growth Rate

CAGR of 5.6% from 2023-2030


Value (USD Billion)


By Type, End-user, and Region

By Type

  • Culture-based Diagnostics

  • Sputum Smear Microscopy

  • Rapid Molecular Diagnostics

  • Others

By End-user

  • Diagnostic Laboratories

  • Hospitals

By Region


  • North America (By Type, By End-user)

    • U.S.

    • Canada

  • Europe (By Type, By End-user)

    • U.K.

    • Germany

    • France

    • Italy

    • Russia

    • Nordic

    • Rest of Europe

  • Asia Pacific (By Type, By End-user)

    • China

    • Japan

    • South Korea

    • Southeast Asia

    • India

    • Australia

    • Rest of Asia Pacific

  • Latin America (By Type, By End-user)

    • Brazil

    • Mexico

    • Rest of Latin America

  • Middle East & Africa (By Type, By End-user)

    • GCC

    • South Africa

    • Rest of the Middle East & Africa

Frequently Asked Questions

Fortune Business Insights says that the global market stood at USD 1.93 billion in 2022 and is projected to reach USD 3.19 billion by 2030.

The market is expected to exhibit a CAGR of 5.6% during the forecast period (2023-2030).

The rapid molecular diagnostics segment is set to lead the market by type.

The key factors driving the market are favorable government policies, high incidence of tuberculosis, and increasing initiatives by market players for the development of technologically advanced products

bioMerieux SA, F. Hoffmann-La Roche Ltd., and Abbott are the top players in the market.

Seeking Comprehensive Intelligence on Different Markets?
Get in Touch with Our Experts

Speak to an Expert
  • Aug, 2023
  • 2022
  • 2019-2021
  • 121


  • $4850

Personalize this Research

  • Granular Research on Specified Regions or Segments
  • Companies Profiled based on User Requirement
  • Broader Insights Pertaining to a Specific Segment or Region
  • Breaking Down Competitive Landscape as per Your Requirement
  • Other Specific Requirement on Customization
Request Customization Banner

Client Testimonials

“This report is really well done and we really appreciate it! Again, I may have questions as we dig in deeper. Thanks again for some really good work.”

- U.S.-based biotechnology company focussing on treatment of chronic pain.

“Kudos to your team. Thank you very much for your support and agility to answer our questions.”

- Europe-based provider of solutions to automate data centre operations.

“We appreciate you and your team taking out time to share the report and data file with us, and we are grateful for the flexibility provided to modify the document as per request. This does help us in our business decision making. We would be pleased to work with you again, and hope to continue our business relationship long into the future.”

- India-based manufacturer of industrial and specialty intermediates with a strong global presence.

“I want to first congratulate you on the great work done on the Medical Platforms project. Thank you so much for all your efforts.”

- One of the largest cosmetics company in the world.

“Thank you very much. I really appreciate the work your team has done. I feel very comfortable recommending your services to some of the other startups that I’m working with, and will likely establish a good long partnership with you.”

- U.S. based startup operating in the cultivated meat market.

“We received the below report on the U.S. market from you. We were very satisfied with the report.”

- Global hearing aids manufacturer.

“I just finished my first pass-through of the report. Great work! Thank you!”

- U.S. based solar racking solutions provider.

“Thanks again for the great work on our last partnership. We are ramping up a new project to understand the imaging and imaging service and distribution market in the U.S.”

- World’s leading advisory firm.

“We feel positive about the results. Based on the presented results, we will do strategic review of this new information and might commission a detailed study on some of the modules included in the report after end of the year. Overall we are very satisfied and please pass on the praise to the team. Thank you for the co-operation!”

- Germany based machine construction company.

“Thank you very much for the very good report. I have another requirement on cutting tools, paper crafts and decorative items.”

- Japanese manufacturing company of stationery products.

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . Privacy.